While pharmacogenomic studies have facilitated the rapid expansion of personalized medicine, the benefits of these findings have not been evenly distributed. Genomic datasets pertaining to Indigenous populations are sorely lacking, leaving members of these communities at a higher risk of adverse drug reactions (ADRs), and associated negative outcomes. Australia has one of the largest Indigenous populations in the world. Pharmacogenomic studies of these diverse Indigenous Australian populations have been hampered by a paucity of data. In this article, we discuss the history of pharmacogenomics and highlight the inequalities that must be addressed to ensure equal access to pharmacogenomic-based healthcare. We also review efforts to conduct the pharmacogenomic profiling of chronic diseases among Australian Indigenous populations and survey the impact of the lack of drug safety-related information on potential ADRs among individuals in these communities.

虽然药物基因组学研究促进了个性化医疗的快速扩展，但这些发现的好处并未平均分配。非常缺乏与土著人口相关的基因组数据集，使这些社区的成员面临更高的药物不良反应 (ADR) 风险和相关的负面结果。澳大利亚拥有世界上最大的原住民人口之一。由于缺乏数据，对这些不同的澳大利亚土著人口的药物基因组学研究受到阻碍。在本文中，我们将讨论药物基因组学的历史，并强调必须解决的不平等问题，以确保平等获得基于药物基因组学的医疗保健服务。